ArticleGastrointestinal endoscopy2017
EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.
Article in Gastrointestinal endoscopy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer.Clinics (Sao Paulo, Brazil) · 2024Pooled it
- Intratumoral injection therapies for locally advanced pancreatic cancer: systematic review.BJS open · 2023Pooled it
- Endoscopic ultrasound-guided injectable therapy for pancreatic cancer: A systematic review.World journal of gastroenterology · 2022Pooled it
- Review
- MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Review
- CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Frontiers in immunology · 2026Review
- Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer.bioRxiv : the preprint server for biology · 2025Article
- Diagnostic value of endoscopic ultrasound in staging of pancreatic cancer.World journal of gastrointestinal oncology · 2025Review
- Endoscopic Ultrasound-Guided Chemoablation of an Acinar Cell Carcinoma as a Suppressive Strategy for Unresectable Disease.ACG case reports journal · 2025Article
- Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025Review
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
- Endoscopic Ultrasound-Guided Ablation of Premalignant Pancreatic Cysts and Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Endoscopic innovations in diagnosis and management of pancreatic cancer: a narrative review and future directions.Therapeutic advances in gastroenterology · 2024Review
- Article
- Review
- State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine.Cancers · 2023Review
- Role of Therapeutic Endoscopic Ultrasound in Management of Pancreatic Cancer: An Endoscopic Oncologist Perspective.Cancers · 2023Review
- EUS-guided interventional therapies for pancreatic diseases.Frontiers in medicine · 2023Review
- Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel.International journal of nanomedicine · 2023Article
- Utility of interventional endoscopic ultrasound in pancreatic cancer.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsAmong the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor desmoplasia. The primary study aim was to determine the toxicity profile of EUS-guided fine-needle injection (EUS-FNI) with gemcitabine. Secondary endpoints included the ability to disease downstage leading to an R0 resection and overall survival (OS) at 6 months, 12 months, and 5 years after therapy.
methodsIn a prospective study from a tertiary referral center, gemcitabine (38 mg/mL) EUS-FNI was performed in patients with PC before conventional therapy. Initial and delayed adverse events (AEs) were assessed within 72 hours and 4 to 14 days after EUS-FNI, respectively. Patients were followed for ≥5 years or until death.
resultsThirty-six patients with stage II (n = 3), stage III (n = 20), or stage IV (n = 13) disease underwent gemcitabine EUS-FNI with 2.5 mL (.7-7.0 mg) total volume of injectate per patient. There were no initial or delayed AEs reported. Thirty-five patients (97.2%) were deceased at the time of analysis with a median 10.3 months of follow-up (range, 3.1-63.9). OS at 6 months and 12 months was 78% and 44%, respectively. The median OS was 10.4 months (range, 2.7-68). Among patients with stage III unresectable disease, 4 (20%) were downstaged and underwent an R0 resection.
conclusionsOur study suggests the feasibility, safety, and potential efficacy of gemcitabine EUS-FNI for PC. Additional data are needed to verify these observations and to determine the potential role relative to conventional multimodality therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.